Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 875-882
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.875
Table 1 Comparison of H long terminal repeat-associating 2 expression and clinicopathological parameters
Cytoplasmic HHLA2 expression
P value1
Negative, n (%)
Low, n (%)
High, n (%)
GenderMale7 (63.64)48 (75.00)9 (52.94)0.193
Female4 (36.36)16 (25.00)8 (47.06)
Pathologic stage of tumorT10 (0.00)0(.00)3(17.65)0.011
T24 (36.36)23(35.94)8(47.06)
T37 (63.64)38(59.38)5(29.41)
T40 (0.00)3(4.69)1(5.88)
Lymphovascular invasionPresent 1 (9.09)8(12.50)2(11.76)0.949
Absent10 (90.91)56(87.50)15(88.24)
Perineural invasionPresent 0 (0.00)2 (3.13)3 (17.65)0.044
Absent11 (100.00)62 (96.88)14 (82.35)
Histologic gradePoorly2 (18.18)11 (17.19)3 (17.65)0.901
Moderately7 (63.64)41 (64.06)9 (52.94)
Well2 (18.18)12 (18.75)5 (29.41)
Tumor stroma ratioLow 4 (36.36)33 (51.56)9 (52.94)0.625
High 7 (63.64)31 (48.44)8 (47.06)
Diameter of tumor (cm)33.11 ± 1.25 (3.00)3.65 ± 1.24 (4.00)2.94 ± 1.03 (3.00)0.0882
Tumor budding degree2.45 ± 0.82 (3.00)2.48 ± 0.80 (3.00)1.88 ± 1.05 (2.00)0.0532
Age459.91 ± 6.33 (60.00)65.38 ± 8.28 (66.00)69.65 ± 8.77 (72.00)0.0052